Neoajuvant polychemotherapy at the complex treatment of the patients with laryngeal cancer
Amiraliev, N.M.
Antibiotiki i Khimioterapiia 47(3): 22-25
2002
ISSN/ISBN: 0235-2990 PMID: 16127903 Document Number: 546318
The treatment of 131 patients with T3.4N0M0 laryngeal cancer was performed by radiation and chemoradiation methods. The efficacy was evaluated of by absence of recurrence, by failure incidence and by survival rate. Of 131 patients investigated 90 had radiation therapy and 41 - chemoradiation treatment with induction polychemotherapy with cisplatin and 5-fluorouracil. Among the patients with T3N0M0 laryngeal cancer (n=65) and T4N0M0 (n=25) after radiation therapy 25(38.5 per cent) patients with T3 and 8 (32 per cent) with T4 lived for more than 3 years without recurrence. Failures were registered for 32 (49.2 per cent) and 13 (52.0 per cent) patients subsequently. 5-year survival was registered for 58.5 and 43.9 per cent of patients with T3 and T4 cancer after additional surgical treatment in the case of recurrence. Neoadjuvant polychemotherapy with cisplatin and 5-fluorouracil improved substantially the results of radiation treatment at the T3.4N0M0 laryngeal cancer. Of the 25 patients with T3.4N0M0 and 16 patients with T4N0M0 treated by radiation the amount of patients without recurrence achieved 16 (64.0 per cent) and 7 (43.7 per cent). Failures were registered at 6 (24 per cent) patients with T3 and at 6 (37.5 per cent) with T4. 5-year survival was registered for 80 per cent patients in T3N0M0 group and for 50 per cent patients in T4N0M0 group. Thus neoadjuvant polychemotherapy with cisplatin and 5-fluorouracil may be recommended as effective and safe method of T34N0M0 laryngeal cancer treatment.